Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
Boston Scientific (NYSE: BSX) has announced two upcoming events:
1. A conference call on October 23, 2024, at 8:00 a.m. ET to discuss third quarter 2024 financial results and business highlights. The call will be hosted by Mike Mahoney, chairman and CEO, and Dan Brennan, executive VP and CFO. Financial results will be released prior to the call.
2. A virtual investor event on October 30, 2024, from 4:00 – 5:00 p.m. ET following the Transcatheter Cardiovascular Therapeutics (TCT) symposium. This event will feature a cardiology business update and Q&A session with key executives from the company's cardiology division.
Live webcasts and replays for both events will be available on the Boston Scientific investor relations website.
Boston Scientific (NYSE: BSX) ha annunciato due eventi imminenti:
1. Una conference call il 23 ottobre 2024 alle 8:00 a.m. ET per discutere i risultati finanziari del terzo trimestre 2024 e i punti salienti aziendali. La chiamata sarà condotta da Mike Mahoney, presidente e CEO, e Dan Brennan, vicepresidente esecutivo e CFO. I risultati finanziari saranno pubblicati prima della chiamata.
2. Un evento virtuale per investitori il 30 ottobre 2024, dalle 4:00 alle 5:00 p.m. ET, dopo il simposio Transcatheter Cardiovascular Therapeutics (TCT). Questo evento presenterà un aggiornamento sul business cardiologico e una sessione di domande e risposte con i principali dirigenti della divisione cardiologica dell'azienda.
I webcast in diretta e le riproduzioni di entrambi gli eventi saranno disponibili sul sito web delle relazioni con gli investitori di Boston Scientific.
Boston Scientific (NYSE: BSX) ha anunciado dos próximos eventos:
1. Una conferencia telefónica el 23 de octubre de 2024, a las 8:00 a.m. ET para discutir los resultados financieros del tercer trimestre de 2024 y los aspectos destacados del negocio. La llamada será dirigida por Mike Mahoney, presidente y CEO, y Dan Brennan, vicepresidente ejecutivo y CFO. Los resultados financieros se publicarán antes de la llamada.
2. Un evento virtual para inversores el 30 de octubre de 2024, de 4:00 a 5:00 p.m. ET, tras el simposio de Terapéuticas Cardiovasculares Transcatéter (TCT). Este evento incluirá una actualización del negocio de cardiología y una sesión de preguntas y respuestas con ejecutivos clave de la división de cardiología de la empresa.
Las retransmisiones en vivo y las repeticiones de ambos eventos estarán disponibles en el sitio web de relaciones con inversionistas de Boston Scientific.
보스턴 사이언티픽(Boston Scientific) (NYSE: BSX)이 다가오는 두 가지 이벤트를 발표했습니다:
1. 2024년 10월 23일 오전 8시(동부 표준시)에 2024년 3분기 재무 결과 및 사업 주요 사항에 대해 논의하는 컨퍼런스 콜이 진행됩니다. 이 콜은 Mike Mahoney 회장 겸 CEO와 Dan Brennan 전무이사 겸 CFO가 주최합니다. 재무 결과는 콜 전에 발표될 예정입니다.
2. 2024년 10월 30일 오후 4시부터 5시까지(동부 표준시) Transcatheter Cardiovascular Therapeutics (TCT) 심포지엄을 끝낸 후 가상 투자자 이벤트가 열립니다. 이 이벤트에서는 심장병 사업 업데이트 및 회사 심장병 부서의 주요 임원들과의 Q&A 세션이 포함됩니다.
두 이벤트 모두 실시간 웹캐스트 및 재생이 보스턴 사이언티픽 투자자 관계 웹사이트에서 제공됩니다.
Boston Scientific (NYSE: BSX) a annoncé deux événements à venir :
1. Une conférence téléphonique le 23 octobre 2024 à 8h00 ET pour discuter des résultats financiers du troisième trimestre 2024 et des temps forts de l'entreprise. L'appel sera animé par Mike Mahoney, président et directeur général, et Dan Brennan, vice-président exécutif et directeur financier. Les résultats financiers seront publiés avant l'appel.
2. Un événement virtuel pour les investisseurs le 30 octobre 2024, de 16h00 à 17h00 ET, après le symposium sur les thérapies cardiovasculaires par cathéter (TCT). Cet événement présentera une mise à jour de l'activité cardiologique et une session de questions-réponses avec des dirigeants clés de la division cardiologique de l'entreprise.
Des webinaires en direct et des rediffusions des deux événements seront disponibles sur le site Web des relations avec les investisseurs de Boston Scientific.
Boston Scientific (NYSE: BSX) hat zwei bevorstehende Veranstaltungen angekündigt:
1. Eine Telefonkonferenz am 23. Oktober 2024 um 8:00 Uhr ET, um die Finanzergebnisse für das 3. Quartal 2024 und die Geschäftshighlights zu erörtern. Die Konferenz wird von Mike Mahoney, Vorsitzendem und CEO, sowie Dan Brennan, Executive VP und CFO, geleitet. Die Finanzergebnisse werden vor der Konferenz veröffentlicht.
2. Eine virtuelle Investorenveranstaltung am 30. Oktober 2024 von 16:00 bis 17:00 Uhr ET im Anschluss an das Symposium für transkatheter-kardiovaskuläre Therapien (TCT). Diese Veranstaltung bietet ein Update zum Kardiologiebereich und eine Q&A-Session mit wichtigen Führungskräften der Kardiologiedivision des Unternehmens.
Live-Webcasts und Wiederholungen beider Veranstaltungen werden auf der Investor-Relations-Website von Boston Scientific verfügbar sein.
- None.
- None.
-Company to also host virtual webcast with a cardiology business update-
The company will also host a virtual investor event on Wednesday, October 30, 2024, from 4:00 – 5:00 p.m. ET following Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). Joe Fitzgerald, executive vice president and president of Cardiology, Dr. Ken Stein, executive vice president and global chief medical officer, Lance Bates, executive vice president and president Interventional Cardiology Therapies (ICTx) and Dr. Janar Sathananthan, chief medical officer ICTx, will present a business update and answer questions from investors.
A live webcast and replay for each event will be accessible at htts://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Jon Monson
Investor Relations
+1 (508) 683-5450
BSXInvestorRelations@bsci.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-conference-call-discussing-third-quarter-2024-results-302265174.html
SOURCE Boston Scientific Corporation
FAQ
When will Boston Scientific (BSX) release its Q3 2024 financial results?
Who will host Boston Scientific's (BSX) Q3 2024 earnings call?
What is the date and time of Boston Scientific's (BSX) virtual investor event following TCT 2024?
Which executives will present at Boston Scientific's (BSX) cardiology business update on October 30, 2024?
